Investment Opportunity

The Company Taking on the Western World's Biggest Public Health Challenge


Cardiol Therapeutics | Listed on: NASDAQ:CRDL | TSX:CRDL.TO

Heart failure is a serious and growing health problem. It’s not only devastating lives, but adds pressure to health care providers and is a growing economic burden. Thankfully, Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is doing something about it, and this clinical-stage company presents an opportunity for you to invest in a potentially life-changing treatment.

Why You Should Consider Investing

  • Treating Diastolic Heart Failure

    Their subcutaneous cannabidiol formulation is an ideal drug candidate for the potential treatment of diastolic heart failure - a growing and costly problem.

  • Acute Myocarditis Cases are Rising

    Under 35s are increasingly susceptible to acute myocarditis, particularly athletes. This is raising concerns and driving interest in workable treatments.

  • Orphan Drug Designation

    The benefits from orphan drug designation include marketing exclusivity rights, high reimbursement levels and regulatory fast-tracking.

  • Independent Board

    Board members are highly qualified, independent and interested in seeing Cardiol succeed.

  • Scientific and Medical Community Backing

    Cardiol’s leadership and advisory teams include some of the biggest names in cardiovascular medicine.

  • Stable Financial Position

    Cardiol Therapeutics is fully funded into 2024 and has no debt.

Company Information

Cardiol Therapeutics Stock Information

Exchange / Symbol
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

Treating CVD with CBD


Cardiol Therapeutics is researching and developing cannabidiol (CBD) as an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD).

Cardiol’s lead product candidate, CardiolRx™, is a pharmaceutically produced oral CBD formulation being clinically developed to treat CVD medicinally.

Many esteemed individuals back Cardiol’s ongoing trials, with promising pre-clinical data showing cannabidiol’s potential anti-fibrotic and anti-inflammatory properties. Their collective backing of the Cardiol Therapeutics journey reassures shareholders that this is a compelling company to invest in.

About the Sector

There are 64.3 million people with heart failure globally and it remains a leading cause of death and hospitalization. Sadly, this problem is mounting and is further exacerbated by obesity, diabetes, hypertension and now COVID-19.

Moreover, the associated annual healthcare costs in the U.S. alone exceed $30bn., making this a substantial economic burden.

If Cardiol Therapeutics achieves its long-term goal of developing a cannabidiol-based treatment for diastolic heart failure, the addressable market will be immense. This is great news for both patients and shareholders alike, as the impact could be life-changing for both.


Acute Myocarditis and Diastolic Heart Failure


Cardiol Therapeutics wants to prove that its flagship drug, CardiolRx™, is a safe and effective treatment for acute myocarditis and that its subcutaneous cannabidiol formulation is a safe and effective treatment for diastolic heart failure. Currently, neither of these life-threatening problems has an approved standard of care.

Acute myocarditis is characterized by inflammation of the heart muscle. It mainly affects people under 35, often males, and can lead to acute heart failure and sudden cardiac death.

Unfortunately, cases of acute myocarditis appear to be rising in response to the COVID-19 virus and from certain mRNA forms of the vaccine.

In short, the market potential in this area of healthcare is immense, and Cardiol’s progress with its clinical trials gives prospective investors a compelling investment case.

Promising Clinical Trials

There’s great excitement for the efficacy of CardiolRx™ in multiple use cases and, as a result, the potential for the company to profit from several revenue streams.

The company’s clinical trials currently focus on proving CardiolRx™ is viable for two potential treatments.

Firstly, Cardiol sees a significant opportunity to develop its oral formulation of CardiolRx™ as an orphan drug to treat acute myocarditis, with a Phase II trial for this commencing soon.

Alongside this, its Phase II/III LANCER study will evaluate the drug’s efficacy and safety in patients hospitalized with COVID-19, who have a prior history of, or risk factors for, CVD.

Besides its two exciting trials, Cardiol Therapeutics is also advancing its development of a subcutaneous cannabidiol formulation. This is to be used as a potential treatment for diastolic heart failure.

A Strong Proposition

Cardiol Therapeutics has assembled some of the biggest names in cardiovascular medicine across its management team, board of directors, scientific advisory board and steering committees for its clinical trials, and their involvement is a powerful endorsement of Cardiol.

As a result, Cardiol presents investors with an intriguing investing opportunity; it is a little-known company operating in a ground-breaking area of science. 


Exclusive Report on Cardiol Therapeutics

Our experts have created an in-depth report on this revolutionary pharmaceutical company. Get this exclusive report delivered straight to your inbox and learn more about this interesting investment opportunity.

What you'll find in our report:

Our Report is a 30+ page comprehensive overview of the business, its operations, unique drug treatments and management team. It includes:

  • A detailed overview of Cardiol Therapeutics

  • Reasons to consider investing

  • Cardiol's unique selling point

  • Information on strong patent protections

  • Cardiol's financial overview and investor outlook

  • Cardiol's prestigious leadership team

  • And much more...

Get Our Exclusive Report Now

Please provide the email address you wish the report to be delivered to.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.